EGFR and adenocarcinoma: In addition, adenocarcinoma (P = 0.022) and EGFR mutation (P = 0.018) were significantly associated with the responsiveness to gefitinib, but no association was found between other clinicopathologic factors and the response to gefitinib therapy (Table 1).